TY - JOUR
T1 - Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer
AU - Chau, Vincent
AU - Madan, Ravi A.
AU - Figg, William D.
N1 - Funding Information:
This work was supported by the National Cancer Institute [ZIA BC 010547].
Publisher Copyright:
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
PY - 2020/10/2
Y1 - 2020/10/2
N2 - The PROfound trial highlights that there is a benefit in testing genes involved in homologous recombination (HR) and forms the rationale for testing in all patients with metastatic, castration-resistant prostate cancer (mCRPC). This trial also demostrates that olaparib improves progression free survival (PFS), objective response rate (ORR), and time to pain progression in patients who harbor alterations in BRCA1, BRCA2, and ATM. These are groundbreaking findings–this is the first trial that demonstrates the efficacy of olaparib versus standard therapy in a genomically-selected patient population with metastatic prostate cancer. Although this trial does not demonstrate improvements in overall survival (OS), we believe that this may be an underestimation based on trial-design. Future studies of olaparib are likely to yield further promising results.
AB - The PROfound trial highlights that there is a benefit in testing genes involved in homologous recombination (HR) and forms the rationale for testing in all patients with metastatic, castration-resistant prostate cancer (mCRPC). This trial also demostrates that olaparib improves progression free survival (PFS), objective response rate (ORR), and time to pain progression in patients who harbor alterations in BRCA1, BRCA2, and ATM. These are groundbreaking findings–this is the first trial that demonstrates the efficacy of olaparib versus standard therapy in a genomically-selected patient population with metastatic prostate cancer. Although this trial does not demonstrate improvements in overall survival (OS), we believe that this may be an underestimation based on trial-design. Future studies of olaparib are likely to yield further promising results.
UR - http://www.scopus.com/inward/record.url?scp=85089863490&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089863490&partnerID=8YFLogxK
U2 - 10.1080/15384047.2020.1809913
DO - 10.1080/15384047.2020.1809913
M3 - Article
C2 - 32844710
AN - SCOPUS:85089863490
VL - 21
SP - 884
EP - 887
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
SN - 1538-4047
IS - 10
ER -